Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG1837 in Cystic Fibrosis with G551D Mutation
NCT02707562Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Feb 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of GLPG1837 in cystic fibrosis (CF), sponsored by Galapagos NV. Primary endpoints: Changes in adverse events up to 9 weeks, Changes in laboratory parameters up to 7 weeks and 2 more. Started Feb 2016; status: completed.
02
Drugs
GLPG1837
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02707562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707562.